10月13日，Moderna盘中下跌3.06%，报206.9美元/股，成交额1.44亿美元。
消息面上，公司在10月9日正式纳入纳斯达克100指数后股价曾连续冲高，叠加个体化癌症疫苗intismeran autogene商业化预期升温，短线涨幅较大；但随着被动资金承接效应逐步消化，最新交易时段获利回吐压力延续。
此前该股前一交易日盘中一度下跌3.28%，当日股价回落6.07%，显示纳指纳入带来的增量催化正边际减弱，短线资金兑现需求升温。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.